Cargando…

Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease

BACKGROUND: Sarcopenia is a significant indicator of the severity of non‐alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk of liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects with metabolic dysfunction‐assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chun, Ho Soo, Kim, Mi Na, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Kim, Seung Up
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517359/ https://www.ncbi.nlm.nih.gov/pubmed/34337887 http://dx.doi.org/10.1002/jcsm.12754

Ejemplares similares

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2022)

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
por: Kim, Yuna, et al.
Publicado: (2022)

Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Sung, Min Je, et al.
Publicado: (2020)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
por: Chang, Jin Won, et al.
Publicado: (2021)

Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Jae Seung, et al.
Publicado: (2021)

Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
por: Seo, Sang Hyun, et al.
Publicado: (2022)

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
por: Kim, Yuna, et al.
Publicado: (2021)

Metabolic Dysfunction–Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study
por: Lee, Hokyou, et al.
Publicado: (2022)

Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
por: Jang, Wonjoon, et al.
Publicado: (2022)

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Kim, David Sooik, et al.
Publicado: (2021)

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
por: Jeon, Mi Young, et al.
Publicado: (2021)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
por: Yun, Byung-Yoon, et al.
Publicado: (2020)

External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
por: Lee, Jae Seung, et al.
Publicado: (2022)

Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Author Correction: Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer
por: Song, Jae Won, et al.
Publicado: (2021)

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
por: Lee, Jae Seung, et al.
Publicado: (2021)

The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
por: Lee, Hye Won, et al.
Publicado: (2021)

Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
por: Lee, Hye Won, et al.
Publicado: (2020)

Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
por: Hwang, Yoon-a, et al.
Publicado: (2023)

THU072 Association Between Nonalcoholic Fatty Liver Disease And Growth Hormone Deficiency In Patients With Nonfunctioning Pituitary Adenoma
por: Hwang, Yoon-a, et al.
Publicado: (2023)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
por: Lee, Jae Seung, et al.
Publicado: (2022)

Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
por: Lee, Jae Seung, et al.
Publicado: (2022)

Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
por: Kim, Mi Na, et al.
Publicado: (2019)

Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
por: Park, Jihye, et al.
Publicado: (2017)

Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
por: Shin, Seunghwan, et al.
Publicado: (2022)

Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
por: Kim, Mi Na, et al.
Publicado: (2016)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis
por: Jo, Min Ho, et al.
Publicado: (2019)

Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy
por: Lee, Hye Won, et al.
Publicado: (2019)

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
por: Lee, Jae Seung, et al.
Publicado: (2020)

Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B
por: Lee, Sangheun, et al.
Publicado: (2015)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
por: Han, Sojung, et al.
Publicado: (2020)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
por: Lim, Tae Seop, et al.
Publicado: (2023)

Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy
por: Cho, In Rae, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r2qm9judaqi63t7it291q9tscq